China-Japan Friendship Hospital
cjfh.com.cnTotal trials
166
Active
89
Phase 3
1
Total enrollment
1,164,628
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 25 of 25 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| semaglutide | — | — | — | — | — | 1 | |
| High-dose ferric derisomaltose | — | — | — | — | — | 1 | |
| Low-dose ferric derisomaltose | — | — | — | — | — | 1 | |
| Wangbi granules | — | — | — | — | — | 1 | |
| Wangbi granules simulant | — | — | — | — | — | 1 | |
| Kuangxiong Aerosol | — | — | — | — | — | 1 | |
| ShengXian-QuYu Decoction | — | — | — | — | — | 1 | |
| Metformin | — | — | — | — | 2 | ||
| BS-GLP group | — | — | — | — | — | 1 | |
| Radiotherapy combined with immunotherapy | — | — | — | — | — | 1 | |
| Macitentan 10 mg tablet, once daily. | — | — | — | — | — | 2 | |
| A Chinese herb formula--Yiwei Jiaohuang Onitment | — | — | — | — | — | 1 | |
| Rabeprazole Enteric-Coated | — | — | — | — | — | 1 | |
| Iron Isomaltoside | — | — | — | — | — | 1 | |
| Physiological saline solution | — | — | — | — | — | 1 | |
| Yiqi Yangyin Formula | — | — | — | — | — | 1 | |
| Yiqi Yangyin Formula placebo | — | — | — | — | — | 1 | |
| Dachengqi decoction | — | — | — | — | — | 1 | |
| Normal Saline | — | — | — | — | — | 1 | |
| JAK Inhibitor | — | — | — | — | — | 1 | |
| Calcineurin Inhibitors | — | — | — | — | — | 1 | |
| Analgesia plan for Anes. Group | — | — | — | — | — | 1 | |
| Analgesia plan for Surg. Group | — | — | — | — | — | 1 | |
| Integrated Disease Management | — | — | — | — | — | 1 | |
| Spleen Invigorating and Weight Reducing Decoction | — | — | — | — | — | 1 |
Next readouts
- 2024-07
- 2025-06-30
- 2025-08-31
- 2025-10-15
- 2025-12-31
- 2026-03-01
- 2026-07-31
- 2026-08-01
- 2026-09-30
- 2026-10-01
Top conditions
- Chronic Obstructive Pulmonary Disease18
- Obesity7
- Pulmonary Embolism6
- Bariatric Surgery6
- Anemia5
- Lung Cancer5
- COPD Exacerbation4
- Heart Failure4
Frequently asked questions about China-Japan Friendship Hospital
- How many clinical trials does China-Japan Friendship Hospital have on ClinicalTrials.gov?
- China-Japan Friendship Hospital is listed as the lead sponsor on 166 clinical trials in ClinicalTrials.gov, 89 of which are currently active (recruiting, enrolling, or ongoing).
- How many of China-Japan Friendship Hospital's trials are in Phase 3?
- 1 of China-Japan Friendship Hospital's trials are in Phase 3, spread across 25 active drug programs.
- What therapeutic areas does China-Japan Friendship Hospital focus on?
- China-Japan Friendship Hospital's most-studied conditions on ClinicalTrials.gov are Chronic Obstructive Pulmonary Disease, Obesity, Pulmonary Embolism, Bariatric Surgery, Anemia.
- When are China-Japan Friendship Hospital's next clinical trial readouts?
- China-Japan Friendship Hospital has 10 upcoming primary-completion readouts tracked here; the soonest is “Combining Chinese Medicine and Nutrition to Enhance Weight Loss After Bariatric Surgery”, expected around 2024-07.